SBBT/TM Program

Specialist in Blood Bank Technology/Transfusion Medicine Program

Interested in SBBT/TM Program?

Program Overview

Specialists in Blood Bank Technology/Transfusion Medicine are certified by the ASCP after meeting specified eligibility criteria and passing the Specialist in Blood Bank (SBB) certification exam. They are knowledgeable in aspects related to blood banking, transfusion medicine, and cellular therapies.

The program is 52-week work-study, onsite training program that provides exposure to a variety of challenging opportunities in practical and theoretical skills in immunohematology and transfusion medicine.

Students are full time employees of the Johns Hopkins Hospital Transfusion Medicine division and must meet employment criteria to be eligible for the Specialist in Blood Bank Technology/Transfusion Medicine (SBBT/TM) program.

There is no tuition or fees for the program, but students are expected to fulfill the employment requirements. Students are responsible for expenses for travel and registration for rotations and enrichment activities.

Program Sponsorship and Accreditation Status

The Johns Hopkins Hospital Specialist in Blood Bank Technology/Transfusion Medicine (SBBT/TM) program is accredited by Commission on Accreditation of Allied Health Education Programs (CAAHEP). CAAHEP and the the Committee on Accreditation of Specialist in Blood Bank Technology Schools (CoA-SBBT) establish and maintain accreditation standards and guidelines for education programs in Specialist in Blood Banking Technology/Transfusion Medicine.

Commission on Accreditation of Allied Health Education Programs (CAAHEP)
9355 - 113th St. N, #7709
Seminole, FL 33775

The Johns Hopkins Hospital Specialist in Blood Bank Technology/Transfusion Medicine program is sponsored by the Johns Hopkins Hospital Medical Laboratories Pathology Department. The Transfusion Medicine division is accredited by the Association for the Advancement of Blood & Biotherapies (AABB) and the College of American Pathologists (CAP).

Association for the Advancement of Blood & Biotherapies (AABB)
4550 Montgomery Avenue, Suite 700 North Tower
Bethesda, MD 20814

College of American Pathologists (CAP)
325 Waukegan Road
Northfield, IL 60093

Program Outcomes

  • 3 year SBB ASCP certification pass rate: 83%
  • 5 year SBB ASCP certification pass rate: 89%
  • 5 year Positive Placement: 100%

Positive placement is defined as the graduate having full or part time employment in a related field, and/or is continuing their education, and/or serving in the military.

Admissions Policy

  • Student qualifications
    • Eligibility for employment at the Johns Hopkins Hospital Medical Laboratories
      1. Applicant may request reasonable accommodation for individuals with disabilities.
    • Baccalaureate degree from a regionally accredited college/university including:
      1. Biology: at least 16 credit hours
      2. Chemistry: at least 16 credit hours
      3. Math: 3 credit hours
      4. Minimum GPA accepted is 2.5 (3.0 GPA preferred)
    • MT, MLS, or BB certification
    • Two years of full time blood bank experience by the program start date is preferred, but candidates who have at least one year of full-time experience in a tertiary medical center transfusion service or blood bank with greater than 400 inpatient beds and has performed specialized immunohematology serologic testing will be considered.
    • Evidence of continuing education
  • Application
    • Application deadline is November 30 for admission in September the following year.
    • Apply for employment at Johns Hopkins Hospital Transfusion Medicine
    • Application materials:
      1. Program application form
      2. Resume/curriculum vitae
      3. Statement of intent (100 words or fewer) - What are your goals for your SBBT/TM training?
      4. Official college/university transcript
      5. Three letters of reference
      6. Statement of continuing education for the past twelve-month period
    • Forward all application materials to:
      Education & Development Coordinator, Transfusion Medicine
      Johns Hopkins Hospital
      Sheikh Zayed Tower 3100
      1800 Orleans Street
      Baltimore Maryland 21287
  • Application Evaluation
    • All completed applications will be disseminated to the admissions committee to determine if an interview will be granted to the applicant.
      1. Incomplete applications will not be considered for admission.
      2. Applicants must meet minimum qualifications to be granted an interview.
  • Interview
    • The applicant will be contacted to arrange a mutual convenient time for an interview with members of the admissions committee.
    • Interviews will typically be conducted in December and January.
    • Applicants will be rated based on:
      1. Academic ability
      2. Job experience
      3. Interview skills
      4. Career goals
      5. Potential to complete the program
  • Status Notification
    • Those accepted for admission to the program will be contacted to offer the position.
      1. Accepted applicants are required to notify the program of their acceptance or declination within thirty (30) days of notification.
        1. If no response is received, the applicant's declination will be assumed.
    • Those not accepted for admission to the program will be sent letters of non-acceptance.
    • Those who have submitted an incomplete application will not be notified of their status.
      1. Incomplete applications will not be considered for the program.
  • Employment
    • Prospective students will be required to become an employee of the Johns Hopkins Hospital Transfusion Medicine division and work a minimum of ninety (90) days prior to the start of the SBB program to allow for training.
    • Acceptance into the program may be rescinded if the prospective student that do not successfully complete the employment probationary period.
  • Advanced Placement, Transfer Credits, and Experiential Learning
    • The Johns Hopkins Hospital Specialist in Blood Banking program does not offer advanced placement, transfer of course credits, or offer credit for experiential learning.

Program Goals

The program is expected to prepare competent entry-level specialists in blood banking technology/transfusion medicine in the cognitive, psychomotor, and affective learning domains and adequately prepare SBB graduates to successfully challenge the ASCP SBB certification exam.

The objective of the Johns Hopkins Hospital SBBT/TM program is to produce a highly trained individual who can function competently in multiple capacities while developing leadership qualities and confidence to work in a flexible and changing environment. The program will develop skills enhancing the student's ability to respond to patient and employee needs by effectively communicating information to a broad variety of individuals.

The graduates of the Johns Hopkins SBBT/TM program will be able to be:

  • Technical Consultant - Serve as a technical resource for utilizing routine and specialized immunohematology and molecular methods to resolve simple and complex serologic cases.
  • Quality Manager - Oversee laboratory quality management programs based on regulatory and accreditation requirements.
  • Manager/Supervisor - Perform laboratory operations and resource management duties.
  • Transfusion Management Consultant - Provide consultation for blood component transfusion based on clinical and laboratory data, pathophysiological processes, evidence-based transfusion guidelines, and patient blood management strategies.
  • Educator - Prepare educational activities in the fields of immunohematology and transfusion medicine.
  • Researcher - Participate in research activities in the fields of immunohematology and transfusion medicine.
  • Community Leader - Promote professional conduct and effective communication with patients, donors, laboratory personnel, other healthcare professionals, and the public.


Required courses in the Johns Hopkins Hospital SBBT/TM Program Curriculum:

  • Fundamentals (Genetics, Biochemistry, Immunology)
  • Quality Management
  • Blood Donation & Components
  • Immunohematology Methods
  • Blood Groups
  • Anemia
  • Hemostasis
  • Transfusion Therapy
  • Cellular Therapy
  • Management
  • Capstone (Research)

Educational Activities

  • Classroom activities - presentations and discussion
  • Reading assignments
  • Supplemental activities - videos, practice worksheets, case studies
  • Written assessments - quizzes, exams, and projects
  • Performance of laboratory testing and procedures
  • Participation in laboratory management activities
  • Participation in student rotations
  • Student presentations
  • Teaching opportunities

Student Attendance Policy

Students are employees of the Johns Hopkins Hospital and are managed by the criteria established in the Attendance Management Policy for employment. Students are required to work 40 hours per week with a maximum of ten absences during the academic year with some exceptions.

All classes in the SBB program are required and punctuality is expected.

Student Withdrawal or Dismissal

A student's matriculation through the Johns Hopkins Hospital SBBT/TM program may be terminated by two means, self-withdrawal or dismissal.

Self-withdrawal: A student may choose to withdrawal from the program at any time for any reason. Withdrawal from the program will not impact their employment status. Students wanting to withdrawal from the program must complete the Voluntary Student Withdrawal form and submit to the Education & Development Coordinator.

Dismissal: Program faculty may decide to remove the student from the program. The reason for dismissal may affect their employment status.
A. Causes that may not affect students employment status:

  1. Failure to maintain an acceptable grade average as measured by examinations and projects.
  2. Failure to complete multiple assignments on time.
  3. Failure to adhere to the attendance policy.
  4. Failure to demonstrate understanding of didactic and technical theory evidence by the student's inability to resolve serologic problems, select appropriate treatment methods, participate in intellectual exchange, or explain concepts that have been previously discussed

Methods for Student Removal:

  1. Unsatisfactory program performance will be discussed with program faculty
  2. Verbal and written warning will be used to notify the student of the unsatisfactory performance.
  3. Follow-up evaluation will take place no later than than one month after the initial written warning. If the student fails to demonstrate improvement, they will be dismissed from the program.

B. Causes that may affect student's employment status:

  1. Failure to follow established hospital personnel policies and procedures.
  2. Failure to follow standard operating procedures

Methods for Student Removal:

  1. Notification and corrective action will follow the Johns Hopkins Medicine Corrective Action policy.
  2. Students receiving a written reprimand as part of corrective action will be dismissed from the program.

Students dismissed from the program who believe they have been treated unfairly, discriminated against, or have had their rights abridged may initiate grievance.

  1. Unsatisfactory academic performance, students ma appeal their dismissal from the program, if the means of assessing the student's academic performance is arbitrary (based on attributes other than performance in the program or are based on unreasonable expectations that are not defined in the program goals and curriculum).
  2. Unsatisfactory work performance, students may appeal their dismissal from the program and/or employment. Students may pursue the Employee Appeals Process if a decision was made by the program that impacted the terms or condition of their education status or employment.

Who are our Graduates?

Year Graduates
1971-1972 Patricia Eska
1972-1973 Sandra Buck (retired)

Randi Passamaneck (retired)

Patricia Wright (retired)
1973-1974 Christine Barrasso (retired)

Sarah Haley Hixon, MT(ASCP), SBB (retired)

Mary Ellen "Mel" Rosche (retired)

Ginny Tyler

Linda C. Winn, MA, MT(ASCP)SBB (retired)
1975-1976 Jane Kuchta (retired)

Michael Baldwin (retired)
1976-1977 Gilliam "Gill" Conley (retired)
1978-1979 Evelyn Hunt Bastian (retired)

Sandra Nance (retired)

Mary Adrian Vansickel
1979-1980 JL Nina Salamon

Jo Anne Zujewski, MD (retired)
1980-1981 Donna Fitzpatrick, MT(ASCP)SBB, CHS(ABHI) (retired)

Barbara Smith, MT(ASCP)SBB

Mary Beth Spaeth, MAS, MT(ASCP)SBB (retired)
1981-1982 Janice Davis-Sproul, MAS, MT(ASCP)SBB (retired)

Janis F. Smith, MAS, MT(ASCP)SBB (retired)
1982-1983 Kim Peck, MA, MT(ASCP)SBB, CMQ/OE(ASQ)
Senior Director, Technical Services Community Blood Center Kansas City MO
1983-1984 Sandra Thoman, MBA, MT(ASCP)SBB (retired)
1984-1985 Gail S. Freund, MT(ASCP)SBB
IRL Technologist, Reference Lab American Red Cross Massachusetts Region Dedham MA
1985-1986 Kevin B. Lawton MT(ASCP)SBB
Transfusion Service Supervisor, Medstar Harbor Hospital Baltimore MD
1986-1987 Bernadette Graves, MT(ASCP)SBB
Lead IRL Tech, Community Blood Center of Greater Kansas City Kansas City MO

Jane Mills, MT(ASCP)SBB (retired)

Anita Richardson, MAS
Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration
1988-1989 Suzy Nicol, MS, MT(ASCP)SBB
Pathology Laboratory Manager II, Johns Hopkins Bayview Medical Center Baltimore MD

Roxanne M. Tata, MT(ASCP)SBB, CQA(ASQ)
Senior Corporate Director of Quality, Bloodsystems, Inc.
1989-1990 Joan Boyd (retired)
1991-1992 William M. Montgomery, Jr. MT(ASCP)SBB
Quality Assurance Technologist, Transfusion Medicine Johns Hopkins Hospital Baltimore MD
1992-1993 Nanette C. Johnson, MT(ASC)SBB (retired)

William Turcan
Program Director, Blood Bank Fellowship Walter Reed National Military Medical Center Bethesda MD
1994-1995 Donna Marquess, FACHE, MA, MT(ASCP)SBB, DLM
Assistant Vice President, Laboratory Services LifeBridge Health Laboratories Baltimore MD

Gerald Rogalski, MSc, PMP, MT(ASCP)SBB
Lead IT, Regional Systems Support Roche Support Network
1995-1996 Donna Mirabella, MS, MT(ASCP)SBB
Associate Technical Director, Blood Bank Stony Brook University Medical Center Stony Brook NY
2003-2004 Dewi N. Fauzie
Holy Cross Health

Parveen F. Halim
Immunohematology Reference Laboratory, American Red Cross
2004-2005 Lorraine N. Blagg, MA, MLS(ASCP)CM SBB
Pathology Education & Development Lead, Johns Hopkins Hospital Baltimore MD
SBBT/TM Program Director, Johns Hopkins Hospital Baltimore MD
Assistant Editor, Transfusion News
2005-2006 Rosalinda "Leny" M. Catamisan, CLS (California), SBB(ASCP)CM
Manager, Transfusion Service & Blood Donor Center Torrance Memorial Medical Center Torrance CA
2006-2007 Gwen Howell, MS, MLS(ASCP)CM SBBCM
Manager, Pathology & Laboratory Medicine Penn State Health, Milton S. Hershey Medical Center Hershey PA
2007-2008 Wei Cai, MBA, MLS(ASCP)CM SBBCM
Supervisor, Transfusion Service Stanford Health Care Standford CA
2008-2009 Yeo-Jin

2009-2010 Justina Pangallo, MS, MLS(ASCP) CM SBBCM
Multi-Site Administrator Clinical Laboratory Operations, Medstar Health Baltimore MD

2010-2011 Peter
2011-2012 Alissa B. Duharme, MLS(ASCP)CM SBBCM
Medical Technologist, St. Agnes Hospital Baltimore MD

Milagros Perez, MT(ASCP)SBBCM
Senior Blood Bank Technologist, Sidra Medical & Research Center Qatar Kuwait

Heather Smetana, MLS(ASCP)CM SBBCM
Supervisor, Transfusion Medicine Johns Hopkins Hospital Baltimore MD
2012-2013 Rebecca Coward, BS, MT(ASCP)SBBCM
Supervisor, Transfusion Services WakeMed Raleigh Campus Raleigh NC

2014-2015 Nadjay Cambre, MLS(ASCP)CM SBBCM
Service Quality Specialist, Becton Dickinson Baltimore MD

2016 Ji Hye Sexton, MLS(ASCP)CM SBBCM
2016-2017 Sean Erony, MLS(ASCP)CM SBBCM
Manager, Clinical Pathology Penn State Health, Milton S. Hershey Medical Center Hershey PA

2017-2018 Mary K. Haddaway, MLS(ASCP)CM SBBCM
Technical Specialist, Transfusion Medicine Johns Hopkins Hospital Baltimore MD
2018-2019 Kayla Erculiani, MLS(ASCP)CM SBBCM
Hemo Bioscience Durham NC
2019-2020 Kristen Buban, MLS(ASCP)CM SBBCM
Transfusion Coordinator II, Transfusion Medicine Johns Hopkins Hospital Baltimore MD

Jordan Ippolito, MLS(ASCP)CM SBBCM
Clinical Project Specialist, Medical Affairs Becton Dickinson Baltimore MD

Karaleigh Leonard, MLS(ASCP)CM SBBCM
Lead Technologist, Transfusion Medicine Johns Hopkins Hospital Baltimore MD
2020-2021 Kyle Forsythe, MLS(ASCP)CM
Clinical Laboratory Scientist 4, Transfusion Medicine Johns Hopkins Hospital Baltimore MD

Transfusion Safety Officer, Long Island Jewish Medical Center Queens NY
2021-2022 Jireh Oncita, MLS(ASCP)CM SBBCM
Supervisor, Immunohematology Reference Laboratory, American Red Cross Baltimore MD
2022 ImmuMADNESS Champion

Xaviera Ramon, MLS(ASCP)CM SBBCM
Clinical Laboratory Scientist 3, Transfusion Medicine Johns Hopkins Hospital Baltimore MD
Adjunct Transfusion Coordinator, Johns Hopkins Hospital Baltimore MD

Our Graduates' Publications

Buban, KR, Lawrence, CE, Zhu, XJ, Tobian, AAR, Gehrie, EA, Vozniak, S, Shrestha, R, Lokhandwala, PM, and Bloch, EM. Algorithm-based selection of automated red blood cell exchange procedure goals reduces blood utilization in chronically transfused adults with sickle cell disease. Journal of Clinical Apheresis, 2022: 1-8.

Blagg LN, Hruban RH, and Gehrie EA. A department-sponsored, hospital-based pathology education symposium is a cost-effective method to provide laboratory staff with highly rated continuing education experiences. Archives of Pathology & Laboratory Medicine, 2020;

Haddaway, K , Bloch, EM, Tobian, AA, Frank, SM, Sikorski, R, Cho, BC, Zheng, G , Jani, J, Lokhandwala, PM, Lawrence, CE, Blagg, L , Ness, PM, Kickler, TS and Gehrie, EA (2019), Hemostatic properties of cold‐stored whole blood leukoreduced using a platelet‐sparing versus a non–platelet‐sparing filter. Transfusion, 59: 1809-1817.

Erony, SM, Marshall, CE, Gehrie, EA, Boyd, JS, Ness, PM, Tobian, AA, Carroll, KC, Blagg, L , Shifflett, L and Bloch, EM. (2018), The epidemiology of bacterial culture–positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. Transfusion, 58: 1933-1939.

Blagg LN. Sulfhydryl treatment of serum or plasma for the reduction of IgM antibodies. Immunohematology, 2018;34:135-139.

Lokhandwala, PM, O'Neal, A , Patel, EU, Brunker, PA, Gehrie, EA, Zheng, G, Kickler, TS, Ness, PM and Tobian, AA. (2018), Hemostatic profile and safety of pooled cryoprecipitate up to 120 hours after thawing. Transfusion, 58: 1126-1131.

Horn T, Hamilton J. Kosanke J, Hare VW, Kluver W, Beres W, Nance S, Keller MA. Assessment of common red blood cell pretreatments to yield an accurate serologicantigen phenotype compared with genotype predicted phenotype. Immunohematology 2017;33:147-151.

Luo X, Keller MA, James I, Grant M, Liu S, Massey KS, Czulewicz A, Nance S, Li Y. Strategies to identify candidates D variant genotyping. Blood Transfusion, 2017 Apr 5:1-9.

Brunker, P.A.R., Ravindran, K., and Shirey, R.S. (2017), Modeling alloantibody formation to high-incidence red blood cell antigens in immune responders using genotypic data. Immunohematology, 33: 9-14.

Nance, S, Scharberg, EA, Thornton, N, Yahalom, V, Sareneva I, Lomas-Francis, C, International rare donor panels: a review. Vox Sanguinis 2016: 110; 209–218.

Beres, W, Meny G, Nance S. A detailed flow cytometric method for detection of low-level in vivo red blood cell–bound IgG, IgA, and IgM. Immunohematology 2016;32:161-169.

Prince SD, Winestone LE, Nance SJ, Friedman DF. Recurrent Donath-­Landsteiner Hemolytic Anemia: A Pediatric Case Report. Transfusion 2016:57: 1401-1406.

Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20;7(288):288ra78.

Gupta, S, Fenves, A, Nance, ST, Sykes, D, and Dzik, W. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion 2015;55:623–628.

Betensky, M, Witmer, C, Fisher, MJ, Nance, S, Weiss, MJ, and Sesok-Pizzini, DA. Immune Hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma. Transfusion 2014;54:2901-2905.

Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattany P, McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo AC, Borrello I, Mendizabal A, Karas TZ, Byrnes J, Lowery M, Heldman AW, Hare JM. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circulation research. 2014;114(8): 1302-10. PMCID: 4104798.

Vege, S, Nance, S, Kavitsky, D, Li, X, Horn, T, Meny, G and Westhoff, CM. A novel AQP1 allele associated with Co(a–b–) phenotype. Immunohematology 2013:29:1-4.

Smith, HM, Shirey, RS, Thoman, SK, and Jackson, JB. (2013), Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology, 29: 127-130.

Eipl K, Nakabiito C, Bwogi K, Motevalli M, Roots A, Blagg L, and Jackson, JB. Seroprevalence of unexpected red blood cell antibodies among pregnant women in Uganda. Immunohematology 2012;28:115–117.

Karafin MS, Blagg L, Tobian AAR, King KE, Ness PM, and Savage WJ. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion, 2012 Oct; 52(10): 2087–2093.

Blagg LN. Transfusion Science, 2nd ed. Joyce Overfield, Maureen Dawson, and David Hamer. Oxfordshire , Scion Publishing Ltd , 2008. (book review). Transfusion 2010; 50: 2281.

Velliquette, RW, Hu, Z, Lomas-Francis, C, Hue-Roye, K, Allen, JL, Mirabella, D and Reid, ME. (2010), Novel single-nucleotide change in GYP*A in a person who made an alloantibody to a new high-prevalence MNS antigen called ENEV. Transfusion, 50: 856-860.

Shirey, RS, Cai, W, Montgomery, RA, Chhibber, V, Ness, PM and King, KE (2010). Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. Transfusion, 50: 631–634.

David M Nguyen, MD, Hun J Lee, MD, Donna Mirabella, MT(ASCP) SBB, Ding Wen Wu, MD, PhD Delayed Hemolytic Transfusion Reaction due to Anti-Jkb: Case Report Highlighting the Importance of Early Blood Bank Consultation and Literature Review North American Journal of Medicine and Science Oct 2010 Vol 3 No.4 187

JR Cruz, DM Harmening, SJ Nance. Summary of the Caribbean sub-regional workshop on quality: a collaborative effort to improve international blood transfusion services. Immunohematology 2008;24:1-3.

S Nance. ISBT Working Party for Rare Donors: 24 years of international collaboration, Transfusion Today 2008;75:4-10.

HW Reesink , CP Engelfriet , H Schennach, et al. Donors with a rare pheno (geno) type. Vox Sanguinis 2008;95:236-253.

S Nance. Operational issues for implementation of donor genotyping for red cell antigens. Transfusion Special Supplement 2007.

DA Sesok-Pizzini, DP Friedman, K Smith-Whitley, SJ Nance. Transfusion support of patients with Sickle Cell Disease at the Children’s Hospital of Philadelphia. Immunohematology 2006;22:121-125.

Bell MJ, Stockwell DC, Luban NL, Shirey RS, Shaak L, Ness PM, Wong EC. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr Crit Care Med. 2005 May;6(3):363-6.

SJ Nance, S Hsu, RR Vassallo, S Murphy. Platelet matching for alloimmunized patients – room for improvement. Immunohematology 2004;20:80-88.

Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. 2004. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 324:269-275.

JR Storry, CM Westhoff, D Charles-Pierre, M Rios, K Hue-Roye, S Vege, S Nance, ME Reid. DNA analysis for donor screening of Dombrock blood group antigens. Immunohematology 2003;19:73-76.

S Mechanic, J Maurer, MJ Igoe, D Kavitsky, S Nance. Anti-Vel reactivity diminished by adsorption with rabbit erythrocyte stroma. Transfusion 2002;42:1180-1183.

Montgomery WM, Nance SJ, Donnelly, SF et al. MAM: a “new” high incidence antigen Found on multiple cell lines. Transfusion 2000;40:1132-1159.

Munizza M, Nance S, Keashen-Schnell MA, Sherwood W and Murphy S. Provision of HPA-1a(PlA1)-negative platelets for neonatal alloimmune thrombocytopenia: screening, testing, and transfusion protocol. Immunohematology, 1999;15:71-74.

Rumsey DH, Sandler SA, Nance, SJ, Rubino M. Naturally occurring anti-Jka in twins detected by solid phase method only. Immunohematology 1999;15:159-162.

Nance S. From Donor to Patient. In: Reid M and Nance S. Red Cell Transfusion: A practical guide. Humana Press, 1997.

Reid ME, Storry JR, Maurer J, Nance S. Practical Method for Determination of the U Status of S-s- erythrocytes. Immunohematology 1997; 13:111-114.

Sandler SG, Mallory DM, Trimble J, Nance SJ. Serological Reactivity of WinRho SD does not differentiate common D+ phenotypes. Blood 1997 (letter).

Shirey, R.S., Mirabella, D.C., Lumadue, J.A. and Ness, P.M. (1997), Differentiation of anti-D, -C, and –G: clinical relevance in alloimmunized pregnancies. Transfusion, 37: 493-496.

Walz T, Hirai T, Murata K, Heymann JB, Mitsuoka K, Fujiyoshi Y, Smith BL, Agre P, and Engel A. 1997. The three-dimensional structure of aquaporin-1. Nature. 387:624-627.

Smith BL, Preston GM, Spring FA, Anstee DJ, and Agre P. 1994. Human red cell Aquaporin CHIP: I. Molecular characterization of ABH and Colton blood group antigens. J Clin Invest. 94:1043-1049.

Lucas, G.F., Hadley A.G., Nance S.J., Garratty G. Predicting haemolytic disease of the newborn: A comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993; 33; 484-487.

Munizza M., Kavitsky D., Schainker B.A., Poyser A., Peek C., Nance S. Hemolytic Anemia Associated with injection of Fluorescein. Transfusion 1993; 33:689-92.

Sacks D.A., Garratty G., Nance S., Petrucha R.A., Horenstein J., Fotheringham N. TheMonocyte monolayer assay as a predictor of severity of erythroblastosis fetalis. American Journal of Perinatology 1993:10; 428-431.

Judd W.J., Steiner E.A., Abruzzo L.V., Davenport R.D., Oberman H.A., Pehta J, Nance S.J. Anti-i causing acute hemolysis following a negative immediate-spin crossmatch. Transfusion 1992; 32:572-575.

Judd W.J., Steiner E.A., Oberman H.A., Nance S. Can the reading for serological reactivity following 37oC incubation be omitted? Transfusion 1992; 32:304-308.

Garratty G., Nance S., Domen R. Fatal immune hemolytic anemia due to cefetetan. Transfusion 1992;32:269-271.

Smith BL, and Agre P. 1991. Erythrocyte Mr 28,000 transmembrane protein exists as a multisubunit oligomer similar to channel proteins. J Biol Chem. 266:6407-6415.

Nance S., Arndt P., Garratty G., Nelson J. Correlation of IgG subclass with the severity of hemolytic disease of the newborn. Transfusion 1990;30:381-382.

Garratty G., Nance S.J. Correlation between in vivo hemolysis and the amount of red cell bound IgG measured by flow cytometry. Transfusion 1990;30:617-621.

Nance S., Nelson J., Arndt P., Lam H., Garratty G.: Quantitation of fetal maternal hemorrhage by flow cytometry, a simple and accurate method. Amer J Clin Pathol 1989;91:288-292.

Nance S., Nelson J., Horenstein J., Arndt P., Platt L., Garratty G. Monocyte monolayer assay - an efficient non-invasive technique for predicting the severity of hemolytic disease of the newborn. Amer J Clin Pathol 1989;92:89-92.

Nance S., Garratty G. Preparation of reticulocyte-rich red cells using LeucoPREP. Transfusion 1989;29:560-561.

Levy G., Selset G., McQuiston D., Nance S., Garratty G., Smith L., Goldfinger D.: Clinical significance of anti-Ytb: Report of a case using a 51 Chromium red cell survival study. Transfusion 1988; 28:265-267.

Denker BM, Smith BL, Kuhajda FP, and Agre P. 1988. Identification, purification, and partial characterization of a novel Mr 28,000 integral membrane protein from erythrocytes and renal tubules. J Biol Chem. 263:15634-15642.

Nance S., Arndt P., Garratty G.: The effect of fresh normal sera on monocyte monolayer assay reactivity. Transfusion 1988;28:398-399.

Nance S., Ladisch S., Williamson T., Garratty G.: Erythromycin-induced immune hemolytic anemia. Vox Sanguinis 1988;55:233-236.

Oien L., Nance S., Arndt P., Garratty G.: Determination of zygosity using flow cytometric analysis of red blood cell antigen strength. Transfusion 1988;28:541-544.

Druzin ML, Wolf CFW, Eidersheim T, Hudon JM, Kogust EA, Salamon J. Donation of blood by the pregnant patient for autologous transfusion. American Journal of Obstetrics and Gynecology, 159:1023, 1988.

Nance S., Arndt P., Garratty G.: Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449-452.

Nance S., Garratty G.: Application of flow cytometry to immunohematology. Journal of Immunological Methods 1987;101:127-131.

Nance S., Garratty G.: Polyethylene glycol: a new potentiator of red cell antigen-antibody reactions. Amer J Clin Pathol 1987;87:633-635.

Postoway N., Nance S., and Garratty G.: Variables affecting the enzyme-linked antiglobulin test when detecting and quantitating IgG red cell antibodies. Med Lab Sci 1985;42:11-19.

Ness PM, Salamon JL. The failure of post injection Rh immune globulin titers to detect large fetal maternal hemorrhages. American Journal of Clinical Pathology, 85-604, 1985.

Kickler TS, Salamon JL, Welsh F, Ness PM, Braine H. A microtiter plate technique for the detection of platelet antibodies and platelet antigen typing. Transfusion, 24:247, 1984.

Garratty G., Postoway N., Nance S., Brunt D.: Spontaneous agglutination of red cells with a positive direct antiglobulin test in various media. Transfusion 1984;24:214-217.

Gibble JW, Salamon JL and Ness PM. Comparison of antibody elution techniques by enzyme linked antiglobulin test (ELAT). Transfusion, 23:300, 1983.

Greenberg A, Winkler R, Smith BL, and Liebman J. 1982. The negatively charged nitrogen in ammonium ion and derived concepts of acidity, basicity, proton affinity, and ion energetics. J Chem Ed. 59:367-370.

Taddie S., Barrasso C., Ness P.M.: Anti-K6 as a cause of delayed hemolytic transfusion reaction. Transfusion 1982;22:68-69.

Riley J.Z., Ness P.M., Taddie S., Barrasso C., Baldwin M.; Detection and quantitation of fetal-maternal bleed utilizing an enzyme-linked antiglobulin test. Transfusion 1982;22:472-474.

Grindon, A. J. and Eska, P. L. Error Rate, Precision, and Accuracy in Immunohematology. Transfusion 1977: 17: 425–430.

Winn, L. C., Eska, P. L. and Grindon, A. J. Anti-Rd (Radin) Following the Transfusion of a Radin Positive Unit of Blood. Transfusion 1976: 16: 351–352.

Winn, L. C., Eska, P. L. and Grindon, A. J. ABO Discrepancy Caused by an Auto Anti-N. Transfusion 1975: 15: 612–613.

Support the Progam

Interested in donating to support the SBB program?
Thank you for your partnership! Donate online by selecting 'Other - please specify' on the Please Designate My Gift to Support dropdown and under 'Please describe', add Specialist in Blood Bank Technology Program. Thank you.